findmyKOL
Clinical trialNCT01840566Active, not recruitingPhase 1Interventional

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment17Non-Hodgkin's Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test the safety of delivering the patients' own immune cells, called T cells, after the high-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Memorial Sloan Kettering at Basking Ridge (limited Protocol Activities)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth (limited Protocol Activities)

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen (limited Protocol Activities)

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Commack (limited Protocol Activities)

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester (limited Protocol Activities)

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering Nassau (limited Protocol Activites)

    Rockville Centre, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

19-28z T CELLSCarmustineCytarabine →Etoposide →Melphalan →Pegfilgrastim →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Apr 2013
Primary completion
30 Apr 2027
Completion
30 Apr 2027
Last update posted
28 May 2026
Registered enrollment
17
Registry id
NCT01840566
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.